FDA regs are not the only drivers of R&D costs

12/20/2012 | Forbes

FDA regulations are often blamed for the high cost of drug development, but drugmakers' business decisions may be the real culprits, writes Bernard Munos. FDA approval requires two successful Phase III trials, but drugmakers performed dozens of trials in support of blockbusters, whether to broaden the indication or in support of marketing, Munos writes. Moreover, the high failure rate of pre-approval Phase III trials seems to indicate that executives are pushing mediocre drug candidates through the pipeline, he writes.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA